NZ732704A - Quinoline carboxamides for use in the treatment of leukemia - Google Patents
Quinoline carboxamides for use in the treatment of leukemiaInfo
- Publication number
- NZ732704A NZ732704A NZ732704A NZ73270415A NZ732704A NZ 732704 A NZ732704 A NZ 732704A NZ 732704 A NZ732704 A NZ 732704A NZ 73270415 A NZ73270415 A NZ 73270415A NZ 732704 A NZ732704 A NZ 732704A
- Authority
- NZ
- New Zealand
- Prior art keywords
- leukemia
- treatment
- quinoline carboxamides
- carboxamides
- quinoline
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14193776 | 2014-11-19 | ||
| PCT/EP2015/075769 WO2016078921A1 (en) | 2014-11-19 | 2015-11-05 | Quinoline carboxamides for use in the treatment of leukemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ732704A true NZ732704A (en) | 2022-01-28 |
Family
ID=51951635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ732704A NZ732704A (en) | 2014-11-19 | 2015-11-05 | Quinoline carboxamides for use in the treatment of leukemia |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10300053B2 (OSRAM) |
| EP (1) | EP3180005B1 (OSRAM) |
| JP (1) | JP6715833B2 (OSRAM) |
| KR (1) | KR102525805B1 (OSRAM) |
| CN (1) | CN107072989B (OSRAM) |
| AU (1) | AU2015348778B2 (OSRAM) |
| BR (1) | BR112017009854B1 (OSRAM) |
| CA (1) | CA2967112C (OSRAM) |
| EA (1) | EA031643B1 (OSRAM) |
| ES (1) | ES2663836T3 (OSRAM) |
| IL (1) | IL252174B (OSRAM) |
| MX (1) | MX379401B (OSRAM) |
| NZ (1) | NZ732704A (OSRAM) |
| PL (1) | PL3180005T3 (OSRAM) |
| WO (1) | WO2016078921A1 (OSRAM) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022010327A (es) | 2020-03-03 | 2022-11-09 | Active Biotech Ab | Tasquinimod o una sal farmaceuticamente aceptable del mismo para el uso en una terapia combinada. |
| EP4582448A3 (en) | 2020-07-23 | 2025-12-10 | Erasmus University Rotterdam Medical Center | S100 proteins as novel therapeutic targets in myeloproliferative neoplasms |
| JP2024503372A (ja) * | 2021-01-18 | 2024-01-25 | アクティブ バイオテック エイビー | 骨髄異形成症候群の処置における使用のためのタスキニモドまたはその薬学的に許容される塩 |
| BR112023023715A2 (pt) | 2021-05-25 | 2024-02-20 | Active Biotech Ab | Pluralidade de partículas compreendendo tasquinimod, composição farmacêutica, unidade de dosagem farmacêutica, uso da pluralidade de partículas ou da composição farmacêutica, e, método para o tratamento do câncer |
| JP2024524158A (ja) | 2021-07-02 | 2024-07-05 | アクティブ バイオテック エイビー | タスキニモドを含有する医薬製品および前記製品の純度を評価する方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| SE0002320D0 (sv) * | 1999-10-25 | 2000-06-21 | Active Biotech Ab | Malignant tumors |
| SE0201778D0 (sv) | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| KR101855195B1 (ko) | 2010-07-09 | 2018-05-08 | 액티브 바이오테크 에이비 | 퀴놀린-3-카르복사미드의 제조 방법 |
| EP2537517A1 (en) * | 2011-06-22 | 2012-12-26 | Active Biotech AB | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide |
| WO2015095833A1 (en) | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Treatment of hematologic cancers |
-
2015
- 2015-11-05 AU AU2015348778A patent/AU2015348778B2/en active Active
- 2015-11-05 MX MX2017006110A patent/MX379401B/es unknown
- 2015-11-05 WO PCT/EP2015/075769 patent/WO2016078921A1/en not_active Ceased
- 2015-11-05 US US15/525,086 patent/US10300053B2/en active Active
- 2015-11-05 EP EP15790143.0A patent/EP3180005B1/en active Active
- 2015-11-05 JP JP2017525360A patent/JP6715833B2/ja active Active
- 2015-11-05 BR BR112017009854-7A patent/BR112017009854B1/pt active IP Right Grant
- 2015-11-05 NZ NZ732704A patent/NZ732704A/en unknown
- 2015-11-05 CA CA2967112A patent/CA2967112C/en active Active
- 2015-11-05 KR KR1020177015989A patent/KR102525805B1/ko active Active
- 2015-11-05 CN CN201580062750.4A patent/CN107072989B/zh active Active
- 2015-11-05 EA EA201791099A patent/EA031643B1/ru not_active IP Right Cessation
- 2015-11-05 ES ES15790143.0T patent/ES2663836T3/es active Active
- 2015-11-05 PL PL15790143T patent/PL3180005T3/pl unknown
-
2017
- 2017-05-09 IL IL252174A patent/IL252174B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016078921A1 (en) | 2016-05-26 |
| CA2967112C (en) | 2023-05-16 |
| MX379401B (es) | 2025-03-11 |
| IL252174B (en) | 2021-02-28 |
| EA201791099A1 (ru) | 2017-10-31 |
| BR112017009854B1 (pt) | 2022-08-23 |
| EP3180005B1 (en) | 2017-12-27 |
| CN107072989B (zh) | 2020-07-03 |
| EA031643B1 (ru) | 2019-01-31 |
| KR102525805B1 (ko) | 2023-04-25 |
| JP6715833B2 (ja) | 2020-07-01 |
| KR20170083121A (ko) | 2017-07-17 |
| PL3180005T3 (pl) | 2018-06-29 |
| IL252174A0 (en) | 2017-07-31 |
| CA2967112A1 (en) | 2016-05-26 |
| CN107072989A (zh) | 2017-08-18 |
| EP3180005A1 (en) | 2017-06-21 |
| JP2017534652A (ja) | 2017-11-24 |
| BR112017009854A2 (pt) | 2018-01-16 |
| AU2015348778A1 (en) | 2017-06-29 |
| MX2017006110A (es) | 2017-07-27 |
| ES2663836T3 (es) | 2018-04-17 |
| US10300053B2 (en) | 2019-05-28 |
| AU2015348778B2 (en) | 2020-12-24 |
| US20170319568A1 (en) | 2017-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW201613872A (en) | IRAK4 inhibiting agents | |
| MA39749A (fr) | Dérivés de pipéridine-dione | |
| GEP20186933B (en) | Substituted dihydroisoquinoline compounds | |
| EP3209653A4 (en) | Process for the preparation of (r,s)-nicotine | |
| TN2019000210A1 (en) | Antitumoral compounds | |
| PH12017501523A1 (en) | Selective bace1 inhibitors | |
| AU2015352440B2 (en) | Compounds | |
| PH12016501252A1 (en) | Novel tetrahydropyridopyrimidine compound or salt thereof | |
| MX2015008829A (es) | Momelotinib deuterado. | |
| PH12018501709A1 (en) | Naphthridinedione derivatives | |
| SA517381678B1 (ar) | مركبات داي هيدرو بيريميدين-2-أون واستخدامها الطبي | |
| NZ730816A (en) | Quinoline carboxamides for use in the treatment of multiple myeloma | |
| GEP20196984B (en) | Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder | |
| NZ732704A (en) | Quinoline carboxamides for use in the treatment of leukemia | |
| ZA201802399B (en) | Aminothiolester compounds or pharmaceutically acceptable salts thereof, for use in the treatment of cancer | |
| SG10201903630UA (en) | Iminosugars useful for the treatment of viral diseases | |
| HUE039425T2 (hu) | 3,4-Diamino-6-klórpirazin-2-karboxamid vegyületek enac által mediált betegségek kezelésére | |
| MX2015012610A (es) | Pacritinib deuterizado. | |
| MX2018002193A (es) | Metodo de uso de quinoxalinilo-piperazinamida. | |
| CA3006413C (en) | Benzo[b][1,6]naphthyridine derivatives as VPPC-tubulin inhibitors | |
| UA90817U (uk) | Сполука 1,1-діетилкарбокси-2-трифторметил-2-(5'-бромуридил-1'-)етилен з потенційними фізіологічними властивостями | |
| UA91886U (uk) | 1-трет-бутокси-3-(2,2,6,6-тетраметил-4-гідроксипіперидино)-2-пропанол | |
| UA90821U (uk) | Сполука 1-1-діетилкарбоксі-2-ізопропокси-2-трифторметилетилен з потенційними фізіологічними властивостями |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 NOV 2023 BY CAMILLA WELLIN / CPA GLOBAL CLARIVATE Effective date: 20221006 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 NOV 2024 BY CPA GLOBAL (PATRAFEE) AB Effective date: 20231005 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 NOV 2025 BY CPA GLOBAL (PATRAFEE) AB Effective date: 20241011 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 NOV 2026 BY CPA GLOBAL (PATRAFEE) AB Effective date: 20251008 |